Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULARGeneric

FASLODEX

FULVESTRANT

Standard Dose
125MG/2.5ML (50MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview FASLODEX is listed in Drugs@FDA under application 021344 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient FULVESTRANT Form and strength SOLUTION;INTRAMUSCULAR - 125MG/2.5ML (50MG/ML) Sponsor ASTRAZENECA Submission history Latest submission status date: 2021-01-19 00:00:00.

Structured Monograph

Clinical summary

Approval overview FASLODEX is listed in Drugs@FDA under application 021344 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient FULVESTRANT Form and strength SOLUTION;INTRAMUSCULAR - 125MG/2.5ML (50MG/ML) Sponsor ASTRAZENECA Submission history Latest submission status date: 2021-01-19 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.